Pemphigus Vulgaris Treatment Market to hit US$ 896.1 Million by 2031 | Major Companies 2026 - F. Hoffmann-La Roche Ltd, Pfizer Inc, Teva Pharmaceutical Industries

Leander, Texas and Tokyo, Japan - Jan.06.2026
As per DataM intelligence research report" The global pemphigus vulgaris treatment market reached US$ 473.4 million in 2023 and is expected to reach US$ 896.1 million by 2031 growing with a CAGR of 8.3% during the forecast period 2024-2031." Advances in immunotherapy and rare disease research are accelerating pemphigus vulgaris treatment options.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/pemphigus-vulgaris-treatment-market?prasad

United States: Recent Industry Developments

✅ In November 2025, argenx announced positive top-line data from a Phase 3 trial of efgartigimod for pemphigus The FcRn blocker showed rapid disease control and steroid-sparing effects It offers a new mechanism of action for patients resistant to Rituximab

✅ In October 2025, Cabaletta Bio initiated a clinical trial for a CAART therapy targeting desmoglein 3 The cellular therapy aims to eliminate only the B cells causing the disease while sparing the immune system It represents a potentially curative "precision immunology" approach

✅ In September 2025, Roche received FDA Fast Track designation for a next-generation anti-CD20 antibody The drug is designed to offer deeper B-cell depletion with subcutaneous administration It improves patient convenience and adherence in maintenance therapy

✅ In August 2025, The International Pemphigus & Pemphigoid Foundation launched a new patient registry The registry collects real-world data on treatment outcomes to support drug development It empowers the rare disease community in the U.S.

Japan: Recent Industry Developments

✅ In December 2025, Chugai Pharmaceutical received approval for a new dosing regimen of Rituxan for pemphigus The update allows for more flexible maintenance dosing to prevent relapse It optimizes the standard of care for Japanese dermatologists

✅ In November 2025, Kyorin Pharmaceutical launched a novel topical JAK inhibitor for mild pemphigus lesions The ointment provides a non-steroidal option for managing oral and skin blisters It improves the quality of life for patients with localized disease

✅ In October 2025, A Japanese research team identified a new biomarker for predicting pemphigus flare-ups The blood test allows doctors to adjust immunosuppression before symptoms appear It advances personalized medicine in autoimmune dermatology

✅ In September 2025, The Japanese Dermatological Association updated its guidelines to include earlier biologic use The guidelines recommend biologics as a first-line steroid-sparing agent It shifts treatment paradigms away from high-dose corticosteroids

Pemphigus Vulgaris Treatment Market: Drivers
The pemphigus vulgaris treatment market is expanding due to increasing awareness of autoimmune blistering disorders. Rising prevalence of rare dermatological diseases drives the need for targeted therapies. Innovations in immunosuppressive and biologic drugs improve efficacy and safety profiles. Regulatory approvals for advanced treatments support adoption. Healthcare infrastructure and dermatology clinics expansion boost patient access. Growing research in rare diseases enhances therapeutic options. Patient support programs increase awareness and treatment adherence.

Market growth is reinforced by the development of novel biologics and combination therapies. Clinical trials for targeted interventions expand treatment possibilities. Healthcare professionals' focus on early diagnosis and effective management drives adoption. Emerging markets show increasing access to dermatology care. Collaborations between pharmaceutical companies and research institutions accelerate innovation. Pemphigus vulgaris treatments are gaining prominence in autoimmune disorder management.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pemphigus-vulgaris-treatment-market?prasad

Pemphigus Vulgaris Treatment Market: Major Players
F. Hoffmann-La Roche Ltd, Pfizer Inc, Teva Pharmaceutical Industries, Novartis AG, Sanofi, AbbVie Inc, AstraZeneca, Zydus Group, GSK Plc and Syntimmune among others.

Segment Covered in the Pemphigus Vulgaris Treatment Market:
By Treatment Type
The market is segmented into Corticosteroids 40%, Immunosuppressants 25%, Biological Therapies 20%, Intravenous Immunoglobulin (IVIG) Therapy 10%, and Others 5%, with corticosteroids dominating due to their effectiveness as first-line therapy for rapid disease control. Immunosuppressants are widely used to reduce steroid dependency. Biological therapies are gaining strong traction due to targeted action and improved safety profiles. IVIG therapy is used in severe and refractory cases. Advancements in biologics and personalized treatment approaches support market growth.

By Route of Administration
Routes of administration include Oral 45%, Parenteral 35%, and Subcutaneous 20%, with oral administration dominating due to ease of use, patient compliance, and long-term management requirements. Parenteral routes are used for biologics and IVIG therapy in hospital settings. Subcutaneous administration is growing with increasing adoption of biologics and self-administered therapies.

By End User
End-users include Hospitals & Clinics 55%, Specialty Dermatology Clinics 35%, and Research & Academic Laboratories 10%, with hospitals and clinics dominating due to availability of multidisciplinary care, access to advanced therapies, and management of severe cases. Specialty dermatology clinics are growing rapidly with increasing disease awareness and specialized treatment protocols. Research and academic laboratories contribute to clinical trials and therapy development. Rising prevalence of autoimmune blistering diseases supports end-user adoption.

Regional Analysis
North America - 40% Share
North America leads with 40% share, driven by advanced healthcare infrastructure, high diagnosis rates, and availability of biologic therapies in the U.S. and Canada. Biological therapies and oral corticosteroids dominate. Hospitals and specialty dermatology clinics are primary end-users. Strong reimbursement frameworks and ongoing clinical research support market growth.

Europe - 25% Share
Europe holds 25% share, supported by increasing adoption of biologics and immunosuppressants in Germany, France, and the UK. Oral and parenteral routes dominate. Hospitals and specialty clinics lead end-users. Government support for rare disease treatment and expanding dermatology research drive regional expansion.

Asia Pacific - 20% Share
Asia Pacific accounts for 20% share, driven by rising disease awareness, improving healthcare access, and growing availability of corticosteroids and immunosuppressants in China, Japan, and India. Oral therapies dominate. Hospitals are primary end-users. Increasing investments in healthcare infrastructure support market growth.

South America - 8% Share
South America records 8% share, with growing diagnosis rates and treatment access in Brazil and Argentina. Corticosteroids and immunosuppressants dominate. Hospitals are primary end-users. Improving healthcare services and awareness initiatives support gradual market growth.

Middle East & Africa - 7% Share
The Middle East & Africa holds 7% share, driven by expanding dermatology care and improved access to treatments in the UAE, Saudi Arabia, and South Africa. Corticosteroids dominate treatment type. Hospitals and clinics are key end-users. Healthcare development initiatives support market adoption.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=pemphigus-vulgaris-treatment-market

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.